Orchasp Limited has secured crucial regulatory approvals for a significant preferential allotment that will help convert existing loan obligations into equity. The company announced on December 12, 2025, that it has received in-principle approval from both major stock exchanges for the proposed share issuance.

Preferential Allotment Details

The regulatory approvals cover the allotment of substantial equity shares with specific financial parameters:

The preferential allotment represents a strategic move to convert existing loan obligations into equity, potentially strengthening the company's balance sheet by reducing debt burden.

Exchange Approvals and Compliance Requirements

Both BSE Limited and NSE of India Limited have granted their in-principle approvals under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the exchanges have emphasized that this approval should not be construed as automatic listing approval for the securities.

The company must ensure strict compliance with multiple regulatory frameworks including:

• Companies Act, 2013
• Securities Contracts (Regulation) Act, 1956
• Securities and Exchange Board of India Act, 1992
• Depositories Act, 1996
• SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
• SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Internal Controls and Trading Restrictions

Both exchanges have advised Orchasp to strengthen internal controls to monitor trades executed by proposed allottees before the allotment of securities. The company must obtain specific undertakings from allottees confirming they will not engage in intra-day trading in the company's scrip or any sale in the scrip until the allotment date.

The exchanges have made it clear that the responsibility lies solely with the issuer company to verify compliance and ensure adherence to applicable provisions, including Regulation 167(6) of SEBI ICDR regulations, 2018.

Post-Allotment Obligations

Upon completion of the allotment, Orchasp will be required to make a listing application without delay, along with applicable fees, as per Regulation 14 of the LODR Regulations. The company must submit this application within twenty days from the date of allotment, as specified in Schedule XIX Para(2) of ICDR Regulations and SEBI circular dated June 21, 2023.

Non-compliance with these timeline requirements will attract penalties as mentioned in the relevant SEBI circular. The exchanges have reserved their right to withdraw the in-principle approval if any information submitted is found to be incomplete, incorrect, misleading, or false.

Orchasp Limited has announced the incorporation of a wholly-owned subsidiary in the United States as part of its strategic expansion into the healthcare technology sector. The new subsidiary, named Orchasp Inc, was incorporated on December 9, 2025, following board approval granted on November 11, 2025.

Strategic Decision and Board Deliberations

The company's Board of Directors initially discussed the revival of an existing dormant subsidiary, Cybermate Infotek Limited Inc, during their meeting on August 11, 2025. However, after evaluating the estimated costs associated with compliance requirements, revival procedures, and name changes, the board concluded that incorporating a new subsidiary would be more cost-effective than reviving the existing entity.

Subsidiary Details and Capitalization

The newly incorporated subsidiary has been established with specific operational objectives and financial structure:

Business Objectives and Platform Focus

The primary purpose of Orchasp Inc centers on expanding the company's healthcare technology offerings in the US market. The subsidiary will focus on two key operational areas:

• Marketing and promotion of the healthcare platform indusayush ( www.indusayush.in )
• Enabling hosting and distribution of mobile applications on Android and iOS platforms

This strategic move positions Orchasp Limited to leverage the US market opportunities in the healthcare technology sector while establishing a dedicated operational base for its digital health initiatives.

Regulatory Compliance

The incorporation has been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and The National Stock Exchange of India Limited about this corporate development, ensuring transparency with stakeholders and regulatory authorities.